肿瘤细胞治疗研究
英文原题：Re-Tooling of γδ T Cells for Cancer Immunotherapy Using Advanced Manufacturing and Genetic Engineering.
使用体外扩增的自体T细胞进行的过继性免疫治疗在多种癌症类型的治疗中取得了显著成功。
使用体外扩增的自体T细胞的过继性免疫治疗已在多种癌症类型的治疗中取得了显著成功。其中最为突出的进展是嵌合抗原受体（CAR）T细胞疗法的出现，该疗法彻底改变了部分血液系统恶性肿瘤的治疗格局。然而，自体CAR T细胞免疫治疗的可扩展性较差，且在实体瘤中疗效有限。因此，人们对可能弥合这些差距的替代策略产生了浓厚兴趣。使用T细胞是一种有吸引力的替代方案，因为T细胞具有内在的抗肿瘤活性，且作为异体药物产品使用时不会引发移植物抗宿主病（GvHD）。在这篇综述中，我们评估了T细胞用于癌症免疫治疗的潜在用途，以及如何通过制造和基因工程的改进来增强这种活性。我们还总结了CAR T细胞疗法的当前临床经验，并讨论了这些发现对下一代细胞免疫治疗的意义。
Adoptive immunotherapy using ex-vivo-amplified autologous T cells has achieved notable success in the treatment of diverse cancer types. Pre-eminent among these developments has been the advent of chimeric antigen receptor (CAR) T cell therapy, which has revolutionised the treatment of selected haematological malignancies. However, autologous CAR T cell immunotherapy is poorly scalable and has demonstrated limited efficacy against solid tumours. Accordingly, there has been significant interest in alternative strategies that may bridge these gaps. The use of T cells is an attractive alternative since they possess intrinsic anti-tumour activity and do not elicit graft versus host disease (GvHD) when employed as an allogeneic drug product. In this review, we evaluate the potential use of T cells for cancer immunotherapy and how manufacturing and genetic engineering refinements can be used to potentiate this activity. We also summarise current clinical experience with CAR T cell therapies and discuss the implications of these findings for the next generation of cellular immunotherapies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
